The action of Palbociclib on the Cell Cycle of Head and Neck Squamous Cell Carcinoma: A Systematic Review

Abstract

This study evaluates the action of Palbociclib in the cell cycle of HPV-negative head and neck squamous cell carcinoma. Initially approved for HER2- and HR + breast cancer. Palbociclib induces cellular senescence, increases the efficacy of Cetuximab, restores p16 function and decreases phosphorylated Rb, suggesting an improvement in survival in both cancers.

Keywords

cyclin-dependent kinase inhibitor proteins - tumor agnostic therapy - squamous cell carcinoma of head and neck - palbociclib - medical oncology

Authors' Contributions

MEBT: conceptualization, data curation, formal analysis, investigation, methodology, project administration, resources, validation, writing – original draft; JPFdS: formal analysis, investigation, resources, validation, writing – original draft; ACdSAH: writing – review & editing, supervision, validation.

Publication History

Received: 16 January 2025

Accepted: 15 June 2025

Article published online:
26 September 2025

• References

• 1 Shin HC, Song DW, Baek WK, Lee SR, Kwon TK, Lee J. et al. Anticancer activity and differentially expressed genes in head and neck cancer cells treated with a novel cyclin-dependent kinase inhibitor. Chemotherapy 2009; 55 (05) 353-362 [Internet]
• 2 Yan L, Zhang W. Precision medicine becomes reality-tumor type-agnostic therapy. Cancer Commun (Lond) 2018; 38 (01) 6 [Internet]
• 3 Lavacchi D, Roviello G, D'Angelo A. Tumor-agnostic treatment for cancer: When how is better than where. Clin Drug Investig 2020; 40 (06) 519-527 [Internet]
• 4 Lewis C, Harvey RD. Precision Oncology Comes of Age: Tumor-Agnostic Approaches. J Adv Pract Oncol 2020; 11 (03) 221-225 [Internet]
• 5 Sung WWY, Chow JCH, Cho WCS. Tumor mutational burden as a tissue-agnostic biomarker for cancer immunotherapy. Expert Rev Clin Pharmacol 2021; 14 (02) 141-143 [Internet]
• 6 Russo A, Incorvaia L, Malapelle U, Del Re M, Capoluongo E, Vincenzi B. et al. The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIF Italian Scientific Societies. Crit Rev Oncol Hematol 2021; 165: 103436 [Internet]
• 7 Michel L, Ley J, Wildes TM, Schaffer A, Robinson A, Chun SE. et al. Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma. Oral Oncol 2016; 58: 41-48 [Internet]
• 8 Hamilton E, Infante JR. Targeting CDK4/6 in patients with cancer. Cancer Treat Rev 2016; 45: 129-138 [Internet]
• 9 Adkins D, Ley J, Neupane P, Worden F, Sacco AG, Palka K. et al. Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial. Lancet Oncol 2019; 20 (09) 1295-1305 [Internet]
• 10 van Caloen G, Machiels J-P. Potential role of cyclin-dependent kinase 4/6 inhibitors in the treatment of squamous cell carcinoma of the head and neck. Curr Opin Oncol 2019; 31 (03) 122-130 [Internet]
• 11 Göttgens E-L, Bussink J, Leszczynska KB, Peters H, Span PN, Hammond EM. Inhibition of CDK4/CDK6 enhances radiosensitivity of HPV negative head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 2019; 105 (03) 548-558 [Internet]
• 12 Billard-Sandu C, Tao Y-G, Sablin M-P, Dumitrescu G, Billard D, Deutsch E. CDK4/6 inhibitors in P16/HPV16-negative squamous cell carcinoma of the head and neck. Eur Arch Otorhinolaryngol 2020; 277 (05) 1273-1280 [Internet]
• 13 Gadsden NJ, Fulcher CD, Li D, Shrivastava N, Thomas C, Segall JE. et al. Palbociclib renders human papilloma virus-negative head and neck squamous cell carcinoma vulnerable to the senolytic agent navitoclax. Mol Cancer Res 2021; 19 (05) 862-873 [Internet]
• 14 Roskoski Jr R. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs. Pharmacol Res 2016; 107: 249-275 [Internet]
• 15 Gao X, Leone GW, Wang H. Cyclin D-CDK4/6 functions in cancer. Adv Cancer Res 2020; 148: 147-169 [Internet]
• 16 Mangini NS, Wesolowski R, Ramaswamy B, Lustberg MB, Berger MJ. Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer. Ann Pharmacother 2015; 49 (11) 1252-1260 [Internet]
• 17 Clark AS, Karasic TB, DeMichele A. et al. Palbociclib (PD0332991)-a Selective and Potent Cyclin-Dependent Kinase Inhibitor: A Review of Pharmacodynamics and Clinical Development. JAMA Oncol 2016; 2 (02) 253-260 [Internet]